How to appeal a Cigna solid-organ transplant denial

The framework that applies to your appeal

Federal law gives you the right to a full and fair internal appeal, then an external review by an independent third party.

Cigna-specific note: Sold its Medicaid Advantage book to HCSC in 2023. Express Scripts (PBM) is Cigna-owned. Frequent class-action litigation around mental health parity.

What Cigna's policy requires for solid-organ transplant

Cited policy: Cigna Tacrolimus Extended-Release Envarsus-XR Coverage Policy

Kidney transplant recipient (adult). Conversion from immediate-release tacrolimus on stable dose, OR de novo per institutional protocol. Brand-name Envarsus-XR over generic IR tacrolimus requires documented clinical justification (tremor / neurotoxicity / non-adherence / PK variability).

How Cigna denies solid-organ transplant — and how to counter it

Where Cigna pushes back: 1) Use generic IR tacrolimus instead; 2) Astagraf-XL preferred over Envarsus-XR; 3) NTI substitution acceptable.

Counter-arguments that hold up: Tacrolimus is FDA-designated NARROW-THERAPEUTIC-INDEX (NTI) drug. ASN 2010 + 2018 ASN/AST consensus — AB-rated bioequivalence does NOT guarantee clinical equivalence; switching requires intensified TDM + clinical judgment. Envarsus-XR MeltDose technology (Tornatore Clin Pharmacokinet 2018) achieves comparable trough exposure at ~30% lower total dose with reduced peak-to-trough fluctuation, lowering tremor + neurotoxicity. STRATO (Bunnapradist AJT 2013) supported FDA Jul 10, 2015 conversion approval. Pinsky AJT 2009 — non-adherence drives 36% of late graft loss; once-daily dosing improves adherence. Document specific patient factors (tremor on IR / non-adherence / PK lability).

What Cigna typically denies for solid-organ transplant

Across Cigna's commercial and Medicare books, denials cluster around a small number of patterns. For solid-organ transplant, expect:

• Mental health parity violations
• Step therapy
• Specialty drug prior auth
• OON balance billing disputes

Treatments most often denied in this category

These are the solid-organ transplant treatments most often flagged for prior auth, step therapy, or medical necessity review:

• Basiliximab (Simulect)
• rATG (Thymoglobulin)
• Alemtuzumab (Campath)
• Tacrolimus IR (Prograf)
• Tacrolimus ER (Astagraf-XL)
• Tacrolimus ER (Envarsus-XR)

How to submit the appeal to Cigna

1. Read the denial letter — note the exact denial reason code and the appeal deadline (180 days from the date on the letter).
2. Gather supporting documentation: physician letter of medical necessity, relevant clinical notes, peer-reviewed citations supporting the treatment for your indication, and the policy or coverage document Cigna cited in the denial.
3. File the appeal through Cigna's portal (members: https://my.cigna.com ; providers: https://cignaforhcp.cigna.com). Standard decision returns within 30 days; expedited urgent appeals return within 72 hours.
4. If denied again, request external review by an independent reviewer within 4 months of the final internal denial. In CT, the state insurance department coordinates external review for fully-insured plans; ERISA self-funded plans use a federal external review through DOL/EBSA.

Clinician or prior-auth team handling this on the practice side? See Cigna's prior-authorization criteria by drug: Cigna PA criteria on ApprovalHelp.